KA
Therapeutic Areas
Indivior Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INV-202 (Buprenorphine LAIN) | Opioid Use Disorder (OUD) | Phase 3 |
| INV-202 (Oral) | Prurigo Nodularis | Phase 2b |
| RBP-7000 (PERSERIS®) | Schizophrenia | Marketed |
| INV-101 | Cannabis Use Disorder | Phase 2 |
| INV-102 | Stimulant Use Disorder | Phase 1 |
| INV-202 (Oral & LAI) | Major Depressive Disorder (MDD) | Preclinical |